ArticleHaematologica2025

Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.

Qian Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.